InterMune to Host Corporate and Product Development Update
BRISBANE, Calif., July 10 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) announced today that the company will host a meeting to
update the investment community on its lead clinical development
programs on Tuesday, July 23, 2002 from 10:00 a.m. to 12:00 p.m. EDT at
the Four Seasons Hotel, 57 East 57th Street in New York.
Members of InterMune's senior management team will review progress with
Actimmune(R) for treatment of idiopathic pulmonary fibrosis and
oritavancin for treatment of gram-positive bacterial infections. World
renown infectious disease expert, Robert C. Moellering, M.D.,
Physician-in-Chief, Chairman Department of Medicine, Beth Israel
Deaconess Medical Center, will also present an overview of how
oritavancin fits into today's antibiotic market.
The event will be webcast live and be available for replay through 11:59
p.m. EDT, July 26, 2002 on the InterMune web site at www.intermune.com
in the "Investor Relations" section. Members of the financial community
who are interested in attending should contact Myesha Edwards at
medwards@intermune.com.
About InterMune
InterMune is a commercially driven biopharmaceutical company focused on
the marketing, development and applied research of life-saving therapies
for pulmonary disease, infectious disease and cancer. For additional
information about InterMune, please visit www.intermune.com.
SOURCE InterMune, Inc.
07/10/2002 |
